Search

Your search keyword '"Pollom, Erqi Liu"' showing total 11 results
Start Over Author "Pollom, Erqi Liu"
11 results on '"Pollom, Erqi Liu"'

2. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants

Author

Taïeb, David, Wanna, George B, Ahmad, Maleeha, Lussey-Lepoutre, Charlotte, Perrier, Nancy D, Nölting, Svenja, Amar, Laurence, Timmers, Henri J L M, Schwam, Zachary G, Estrera, Anthony L, Lim, Michael, Pollom, Erqi Liu, Vitzthum, Lucas, Bourdeau, Isabelle, Casey, Ruth T, Castinetti, Frédéric, Clifton-Bligh, Roderick, Corssmit, Eleonora P M, de Krijger, Ronald R, Del Rivero, Jaydira, Eisenhofer, Graeme, Ghayee, Hans K, Gimenez-Roqueplo, Anne-Paule, Grossman, Ashley, Imperiale, Alessio, Jansen, Jeroen C, Jha, Abhishek, Kerstens, Michiel N, Kunst, Henricus P M, Liu, James K, Maher, Eamonn R, Marchioni, Daniele, Mercado-Asis, Leilani B, Mete, Ozgur, Naruse, Mitsuhide, Nilubol, Naris, Pandit-Taskar, Neeta, Sebag, Frédéric, Tanabe, Akiyo, Widimsky, Jiri, Meuter, Leah, Lenders, Jacques W M, and Pacak, Karel

Published
2023
Full Text
View/download PDF

3. Single- Versus Multi-Fraction Spine Stereotactic Radiosurgery (ALL-STAR) for Patients with Spinal Metastases: a Randomized Phase III Trial

Author

Pratapneni, Aniket, primary, Klebaner, Daniella, additional, Soltys, Scott Gerard, additional, Rahimy, Elham, additional, Gibbs, Iris Catrice, additional, Chang, Steven Daniel, additional, Li, Gordon, additional, Gephart, Melanie Hayden, additional, Veeravagu, Anand, additional, Szalkowski, Gregory Arthur, additional, Gu, Xuejun, additional, Wang, Lei, additional, Chuang, Cynthia, additional, Liu, Lianli, additional, Jackson, Scott, additional, Skerchak, Jillian Adele, additional, Huang, Kelly Zhe, additional, Wong, Samantha, additional, Brown, Eleanor, additional, and Pollom, Erqi Liu, additional

Published
2024
Full Text
View/download PDF

5. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants

Author

Pathologie Pathologen staf, Taïeb, David, Wanna, George B., Ahmad, Maleeha, Lussey-Lepoutre, Charlotte, Perrier, Nancy D., Nölting, Svenja, Amar, Laurence, Timmers, Henri J.L.M., Schwam, Zachary G., Estrera, Anthony L., Lim, Michael, Pollom, Erqi Liu, Vitzthum, Lucas, Bourdeau, Isabelle, Casey, Ruth T., Castinetti, Frédéric, Clifton-Bligh, Roderick, Corssmit, Eleonora P.M., de Krijger, Ronald R., Del Rivero, Jaydira, Eisenhofer, Graeme, Ghayee, Hans K., Gimenez-Roqueplo, Anne Paule, Grossman, Ashley, Imperiale, Alessio, Jansen, Jeroen C., Jha, Abhishek, Kerstens, Michiel N., Kunst, Henricus P.M., Liu, James K., Maher, Eamonn R., Marchioni, Daniele, Mercado-Asis, Leilani B., Mete, Ozgur, Naruse, Mitsuhide, Nilubol, Naris, Pandit-Taskar, Neeta, Sebag, Frédéric, Tanabe, Akiyo, Widimsky, Jiri, Meuter, Leah, Lenders, Jacques W.M., Pacak, Karel, Pathologie Pathologen staf, Taïeb, David, Wanna, George B., Ahmad, Maleeha, Lussey-Lepoutre, Charlotte, Perrier, Nancy D., Nölting, Svenja, Amar, Laurence, Timmers, Henri J.L.M., Schwam, Zachary G., Estrera, Anthony L., Lim, Michael, Pollom, Erqi Liu, Vitzthum, Lucas, Bourdeau, Isabelle, Casey, Ruth T., Castinetti, Frédéric, Clifton-Bligh, Roderick, Corssmit, Eleonora P.M., de Krijger, Ronald R., Del Rivero, Jaydira, Eisenhofer, Graeme, Ghayee, Hans K., Gimenez-Roqueplo, Anne Paule, Grossman, Ashley, Imperiale, Alessio, Jansen, Jeroen C., Jha, Abhishek, Kerstens, Michiel N., Kunst, Henricus P.M., Liu, James K., Maher, Eamonn R., Marchioni, Daniele, Mercado-Asis, Leilani B., Mete, Ozgur, Naruse, Mitsuhide, Nilubol, Naris, Pandit-Taskar, Neeta, Sebag, Frédéric, Tanabe, Akiyo, Widimsky, Jiri, Meuter, Leah, Lenders, Jacques W.M., and Pacak, Karel

Published
2023

6. Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms

Author

No, Hyunsoo Joshua, primary, Raja, Neelufar, additional, Von Eyben, Rie, additional, Das, Millie, additional, Roy, Mohana, additional, Myall, Nathaniel, additional, Neal, Joel, additional, Wakelee, Heather, additional, Chin, Alexander, additional, Diehn, Maximilian, additional, Loo, Billy Wiseman, additional, Chang, Daniel Tandel, additional, Pollom, Erqi Liu, additional, and Vitzthum, Lucas Kas, additional

Published
2022
Full Text
View/download PDF

8. Radiotherapy for brain metastases from thyroid cancer: an institutional and national retrospective cohort study

Author

Blomain, Erik Scott, primary, Berta, Scott, additional, Hug, Nicholas Fackler, additional, Giao, Duc M., additional, Meola, Antonio, additional, Binkley, Michael Sargent, additional, Hui, Caressa, additional, Churilla, Thomas, additional, Shahsavari, Nastaran, additional, Desai, Kaniksha, additional, Chang, Steven Daniel, additional, Soltys, Scott, additional, and Pollom, Erqi Liu, additional

Published
2022
Full Text
View/download PDF

9. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHDpathogenic variants

Author

Taïeb, David, Wanna, George B, Ahmad, Maleeha, Lussey-Lepoutre, Charlotte, Perrier, Nancy D, Nölting, Svenja, Amar, Laurence, Timmers, Henri J L M, Schwam, Zachary G, Estrera, Anthony L, Lim, Michael, Pollom, Erqi Liu, Vitzthum, Lucas, Bourdeau, Isabelle, Casey, Ruth T, Castinetti, Frédéric, Clifton-Bligh, Roderick, Corssmit, Eleonora P M, de Krijger, Ronald R, Del Rivero, Jaydira, Eisenhofer, Graeme, Ghayee, Hans K, Gimenez-Roqueplo, Anne-Paule, Grossman, Ashley, Imperiale, Alessio, Jansen, Jeroen C, Jha, Abhishek, Kerstens, Michiel N, Kunst, Henricus P M, Liu, James K, Maher, Eamonn R, Marchioni, Daniele, Mercado-Asis, Leilani B, Mete, Ozgur, Naruse, Mitsuhide, Nilubol, Naris, Pandit-Taskar, Neeta, Sebag, Frédéric, Tanabe, Akiyo, Widimsky, Jiri, Meuter, Leah, Lenders, Jacques W M, and Pacak, Karel

Abstract

Patients with germline SDHDpathogenic variants (encoding succinate dehydrogenase subunit D; ie, paraganglioma 1 syndrome) are predominantly affected by head and neck paragangliomas, which, in almost 20% of patients, might coexist with paragangliomas arising from other locations (eg, adrenal medulla, para-aortic, cardiac or thoracic, and pelvic). Given the higher risk of tumour multifocality and bilaterality for phaeochromocytomas and paragangliomas (PPGLs) because of SDHDpathogenic variants than for their sporadic and other genotypic counterparts, the management of patients with SDHDPPGLs is clinically complex in terms of imaging, treatment, and management options. Furthermore, locally aggressive disease can be discovered at a young age or late in the disease course, which presents challenges in balancing surgical intervention with various medical and radiotherapeutic approaches. The axiom—first, do no harm—should always be considered and an initial period of observation (ie, watchful waiting) is often appropriate to characterise tumour behaviour in patients with these pathogenic variants. These patients should be referred to specialised high-volume medical centres. This consensus guideline aims to help physicians with the clinical decision-making process when caring for patients with SDHDPPGLs.

Published
2023
Full Text
View/download PDF

11. Increased Occurrence of Malignancy Before and after Chemoradiation for Anal Squamous Cell Carcinoma: A Multi-Institutional Analysis.

Author

Kumar R, Hallemeier CL, Chang DT, Lu SE, Hathout L, Hristidis VC, Jethwa KR, Baclay JRM, Manne V, Chakrani Z, Haddock MG, Toesca DAS, Pollom EL, Wu AJ, Sandhyavenu H, Romesser PB, and Jabbour SK

Abstract

Background: Anal squamous cell carcinoma (ASCC) is a rare cancer with increased occurrence of multiple cancers before and after the ASCC diagnosis. However, there is limited data on this aspect. This multi-institutional analysis aimed to define the occurrence of malignancies before and after ASCC, time trends, impact on survival, and identify prognostic factors., Material and Methods: Initial primary malignancy (IPM) was defined as a malignancy occurring before the ASCC. Second primary malignancy (SPM) was defined as a distinct primary cancer that developed after ASCC diagnosis. Retrospective multi-institutional chart review was done. Progression free survival (PFS), overall survival (OS) and prognostic factors were evaluated., Results: 647 patients with ASCC treated with curative intent were analyzed. Median age was 61.23 years with 72% as females. 150 patients (23.3%) had multiple malignancies with IPM in 16% and SPM in 8%. Patients without prior cancer had better 5-year PFS (81.2% vs 67.2%, p = .011) and OS (81% vs 69%, p = .008) compared to those with prior cancer. SPMs had a significant adverse impact on PFS (HR 4.22) and OS (HR 3.56). Females had better 5-year PFS (82% vs 70%, p = .016) as compared to males. The median time interval for developing ASCC (as SPM) after IPM was 9.32 years., Conclusions: ASCC patients have increased risk of multiple malignancies. Patients with prior cancer have inferior outcomes. SPM is a poor prognostic factor in patients without any prior cancer. SPM can develop years after treatment of primary ASCC., (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results